- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01538797
Effect of Single Doses of YF476 on Stomach Acidity Compared With Ranitidine and Placebo in Fasted and Fed States
February 20, 2012 updated by: Trio Medicines Ltd.
YF476: Effects of a Single Dose at 3 Dose Levels on 24-hour Ambulatory Gastric pH Compared With Placebo and Ranitidine in Healthy Volunteers
The objectives of the study were:
- To compare a single dose of YF476 at 3 dose levels, placebo and ranitidine with respect to their effects on basal- and food- stimulated gastric pH in healthy volunteers.
- To assess whether there is a relationship between the pharmacokinetics of YF476 and gastric pH in healthy volunteers.
- To assess the safety and tolerability of single doses of YF476 in healthy volunteers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
YF476 is clearly a potent and selective gastrin/CCK-B antagonist and should inhibit basal and meal-stimulated gastric acid secretion and enhance gastric emptying of a liquid meal in man.
Therefore YF476 might benefit patients with reflux oesophagitis.
The compound has been well tolerated in animal toxicity studies at doses in excess of the projected therapeutic dose in patients, and merits studies in healthy volunteers.
Extrapolation from data obtained in animals suggests that a single oral dose of about 10mg of YF476 should compare favourably with an oral dose of 150mg of ranitidine in man with respect to effect on basal and food-stimulated gastric acid secretion.
Therefore in the proposed study a range of doses of YF476 encompassing that dose will be studied; the exact dose of YF476 will be chosen on the basis of the previous study but the top dose will not exceed 100mg.
24-hour ambulatory gastric pH will be monitored via an intragastric pH electrode (7-10).
Although there is variability between subjects with respect to the effects of food and drug treatment on gastric pH, the methodology for measurement of ambulatory gastric pH is robust.
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom, NW10 7EW
- Hammersmith Medicines Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female and aged 18-45 years.
- No clinically relevant abnormal findings in the clinical history or physical examination at the screening assessment which could interfere with the objectives of the study or make the subject's participation hazardous.
- No clinically relevant abnormal laboratory values at the screening evaluation (Attachment 2).
- A normal ECG at the screening examination.
- A body mass index (Quetelet index) in the range 19-30:
- Body Mass Index = weight [kg]_ height [m]2
- Normal blood pressure and heart rate at the screening examination, i.e. BP 90-150mmHg systolic, 40-95mmHg diastolic; heart rate 40-100 beats/min in seated position.
- Subjects must be of sufficient intelligence to understand the nature of the study and any hazards of their participation in it. They must be able to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire study.
- Subjects must give their written consent to participate after reading the Information-for-Volunteers Leaflet and Consent Form, and after having the opportunity to discuss the study with the Investigator or his deputy.
Exclusion Criteria:
- Females who are pregnant or lactating, or who are sexually active and are not using a reliable method of contraception.
- Clinically relevant abnormal history or physical findings at the screening assessment, which could interfere with the objectives of the study or the safety of the subject's participation.
- Clinically relevant abnormalities of laboratory values or ECG at screening evaluation.
- Presence of acute or chronic illness or history of chronic illness sufficient to invalidate subject's participation in the study or make it unnecessarily hazardous.
- Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease or history of any psychotic mental illness.
- Participation in other clinical studies of a new chemical entity or a prescription medicine within the previous 3 months.
- Presence or history of drug or alcohol abuse, or intake of more than 40 units of alcohol weekly.
- Loss of more than 400mL blood during the 3 months before the study, e.g. as a blood donor.
- Use of prescription medication during 30 days before the study.
- Use of an over-the-counter medicine during 7 days before the study
- Blood pressure or heart rate outside those values specified under inclusion criterion (f).
- Possibility that the subject will not cooperate with the requirements of the protocol.
- Evidence of drug abuse on urine testing at study entry.
- Positive test for hepatitis B or C or HIV 1 & 2.
- High risk of hepatitis or HIV infection.
- History of severe allergic disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinically relevant changes from baseline in safety assessments
Time Frame: 6 weeks
|
Physical examination, ECG and safety tests of blood/urine at screening, 24h after dosing on each Treatment Day and at follow up.
Blood pressure and heart rate before and at 0.5, 1, 2, 4, 6, 8, 12 and 24h after dosing on each Treatment Day.
|
6 weeks
|
Numbers of adverse events
Time Frame: 6 weeks
|
Adverse events throughout the study
|
6 weeks
|
Pharmacokinetic parameters: Cmax, Tmax, AUC 0-24 h, T1/2
Time Frame: 6 weeks
|
Blood samples (8mL) before and at 0.5, 1, 2, 4, 6, 8, 12 and 24h after each dose for assay of YF476.
|
6 weeks
|
Pharmacodynamic parameters: continuous 24 h ambulatory gastric pH
Time Frame: 6 weeks
|
Recording starts 0.5h before dosing on each Treatment Day; meals taken at 4, 9, 13 & 22h after dosing.
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 1996
Primary Completion (ACTUAL)
August 1, 1996
Study Completion (ACTUAL)
August 1, 1996
Study Registration Dates
First Submitted
February 15, 2012
First Submitted That Met QC Criteria
February 20, 2012
First Posted (ESTIMATE)
February 24, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
February 24, 2012
Last Update Submitted That Met QC Criteria
February 20, 2012
Last Verified
February 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Stomach Diseases
- Gastroenteritis
- Intestinal Diseases
- Esophageal Diseases
- Peptic Ulcer
- Duodenal Diseases
- Esophagitis, Peptic
- Esophagitis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Gastrointestinal Agents
- Anti-Ulcer Agents
- Histamine Antagonists
- Histamine Agents
- Histamine H2 Antagonists
- Ranitidine
- Ranitidine bismuth citrate
Other Study ID Numbers
- 96-016
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Reflux Oesophagitis
-
Trio Medicines Ltd.Ferring PharmaceuticalsCompletedReflux OesophagitisUnited Kingdom
-
Trio Medicines Ltd.Ferring PharmaceuticalsCompletedReflux OesophagitisUnited Kingdom
-
Trio Medicines Ltd.Ferring PharmaceuticalsCompletedReflux OesophagitisUnited Kingdom
-
AstraZenecaCompletedGastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,"Non-erosive Reflux Disease, Zollinger-Ellison SyndromeJapan
-
MEDA Pharma GmbH & Co. KGICON plc; Clinipace Worldwide; Trium Analysis Online GmbHTerminated
-
University of Kansas Medical CenterUniversity of Texas, Southwestern Medical Center at DallasRecruitingBarrett Oesophagitis With DysplasiaUnited States
-
Universitair Ziekenhuis BrusselUnknownAcid Reflux Esophagitis | Non-acid Reflux EsophagitisBelgium
-
University Hospital MuensterCompletedReflux, Gastroesophageal | Reflux Disease | Reflux, LaryngopharyngealGermany
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedGastroesophageal Reflux Disease | GERD | Acid Reflux | RefluxUnited States
-
Klinikum Garmisch-PatenkirchenNot yet recruitingReflux, Gastroesophageal | Gastro-esophageal RefluxGermany
Clinical Trials on YF476
-
Trio Medicines Ltd.Columbia University; University of CambridgeCompleted
-
Trio Medicines Ltd.Royal Liverpool University HospitalCompletedHypergastrinaemia | Chronic Atrophic Gastritis | Type I Gastric CarcinoidsUnited Kingdom
-
Trio Medicines Ltd.Norwegian University of Science and TechnologyTerminatedChronic Atrophic Gastritis | Hypergastrinemia | Type I Gastric CarcinoidsNorway
-
Trio Medicines Ltd.James Black FoundationCompleted
-
Trio Medicines Ltd.Ferring PharmaceuticalsCompletedReflux OesophagitisUnited Kingdom
-
Trio Medicines Ltd.Ferring PharmaceuticalsCompletedReflux OesophagitisUnited Kingdom
-
Trio Medicines Ltd.National Institutes of Health (NIH)TerminatedZollinger-Ellison Syndrome
-
Trio Medicines Ltd.James Black FoundationCompleted
-
Columbia UniversityTrio Medicines Ltd.CompletedBarrett's EsophagusUnited States, United Kingdom
-
Trio Medicines Ltd.CompletedDyspepsia | ECL-cell Hyperplasia | Parietal-cell Hyperplasia | Rebound Hyperacidity